Time and diseases change. So must our approach and knowledge.
Our technical partner – Baroque Pharmaceuticals, runs a multi-million dollar R & D center in India. It is at this center that our ideas are tested, refined and developed to address identified market needs.
Beyond looking for new molecules, we actively search for new uses and enhanced combinations.
Zitclav – our broad spectrum antibiotic is the first combination of cefuroxime and clavulanic acid registered in Nigeria. This is our contribution to reducing the growing incidence of bacterial resistance to cefuroxime.